MARKET

AZRX

AZRX

AzurRx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.600
-0.150
-4.00%
Opening 10:18 09/20 EDT
OPEN
3.700
PREV CLOSE
3.750
HIGH
3.700
LOW
3.510
VOLUME
136.75K
TURNOVER
--
52 WEEK HIGH
26.30
52 WEEK LOW
3.510
MARKET CAP
33.57M
P/E (TTM)
-0.2020
1D
5D
1M
3M
1Y
5Y
Why AzurRx BioPharma's Stock Is Trading Higher Today
AzurRx BioPharma (NASDAQ:AZRX) shares are trading higher after the company announced it will acquire First Wave Bio.
Benzinga · 5d ago
36 Stocks Moving In Tuesday's Mid-Day Session
Gainers FuelCell Energy, Inc. (NASDAQ: FCEL) shares jumped 26% to $7.08 after the company reported better-than-expected Q3 results. BELLUS Health Inc. (NASDAQ: BLU) shares climbed 25.5% to $6.00. The company on Monday announced interim analysis from the Ph...
Benzinga · 5d ago
AzurRx (AZRX) Announces First Wave Bio Acquisition for $229M
AzurRx BioPharma (AZRX) acquires First Wave Bio for $229 million. Following the acquisition, the company is set to rename itself as First Wave BioPharma.
Zacks · 5d ago
NNVC, LIFE and DATS pre market gainers
Communications Systems JCS +27% declares $3.50 special dividend NanoViricides (NYSE:NNVC) +21% completes licensing for Coronavirus field which includes current COVID-19 drug development aTyr Pharma (NASDAQ:LIFE) +13%. DatChat (NASDAQ:DATS) +10%. SeaChange ...
Seekingalpha · 6d ago
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13)
Benzinga · 6d ago
72 Biggest Movers From Yesterday
Gainers
Benzinga · 6d ago
Top Premarket Gainers
MT Newswires · 6d ago
AzurRx BioPharma To Acquire First Wave Bio For $229M
Benzinga · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AZRX. Analyze the recent business situations of AzurRx through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AZRX stock price target is 23.33 with a high estimate of 30.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 43
Institutional Holdings: 2.83M
% Owned: 30.31%
Shares Outstanding: 9.33M
TypeInstitutionsShares
Increased
12
233.20K
New
5
53.02K
Decreased
2
1.80K
Sold Out
7
25.67K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.60%
Pharmaceuticals & Medical Research
-0.98%
Key Executives
Chairman/President/Chief Executive Officer/Director
James Sapirstein
Chief Financial Officer
Daniel Schneiderman
Other
James Pennington
Lead Director/Independent Director
Edward Borkowski
Director
Terry Coelho
Independent Director
Charles Casamento
Independent Director
Gregory Oakes
Independent Director
Alastair Riddell
Independent Director
Vern Schramm
No Data
About AZRX
AzurRx BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. It focused on developing its pipeline of gut-restricted GI clinical drug candidates, including MS1819 and niclosamide. Its therapeutic product pipeline consists of three clinical-stage programs. The Company’s lead drug candidate is MS1819. It is a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). It is an an oral non-systemic biologic capsule. MS1819 is in two Phase II CF clinical trials. It is a pro-inflammatory pathway inhibitor, is a prescription small molecule drug that has been safely used on millions of patients.

Webull offers kinds of AzurRx BioPharma Inc stock information, including NASDAQ:AZRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AZRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AZRX stock methods without spending real money on the virtual paper trading platform.